Today's News on Maygen, Inc.
Maxygen Announces $10 Million Stock Repurchase Program
[Business Wire] - Maxygen, Inc. , a biotechnology company, today
announced that its Board of Directors has approved a new stock
repurchase program under which the company may purchase up to
$10.0 million of its common stock through December 31, 2012.
34 Stocks With Over 10% Return On Equity Selling For Less Than Book, Part 6: Services
Prolor Biotech: De-Risked And Ready To Begin Phase 3 Trials
3 Attractive, Low P/E Ratio Stocks And More With Safe Credit Scores
MAXYGEN INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Maxygen Announces BARDA Decision Not To Award Contract for Development of MAXY-G34 for Acute Radiation Syndrome
[Business Wire] - Maxygen, Inc. today announced that it has been
advised by the Biomedical Advanced Research and Development
Authority that Maxygen?s proposal for the development of its
MAXY-G34 product candidate as a potential medical countermeasure
for Acute Radiation Syndrome will not be considered for a
contract award.
Stock Option Volatility Trading